To The Moon

Hey, this is Stocks_Pedia.

Here I would like to introduce you to some unfamiliar companies that you may probably haven't heard of, and hope it can be of some help to your investments.

The company I'm going to introduce this time is $Merck(MRK)$.

It went public on 15th May 1946.

[Company Profile]

Merck Pharmaceuticals, Inc. was incorporated in New Jersey in 1970. The company is a global healthcare company providing innovative health solutions through its prescription drugs, vaccines, biotherapeutics and animal health products.

The company's operations are managed primarily on a product basis and include four operating divisions, namely Pharmaceuticals, Animal Health, Healthcare Services and Alliances.

[History & Events]

1953: Merck & Co. merged with Philadelphia-based Sharp & Dohme, Inc., becoming the largest U.S. drugmaker.

1970: Merck was incorporated in New Jersey.

1982: Merck formed a joint venture, KBI Inc., with AstraZeneca.

1985: Merck received approval for imipenem, the first member of the carbapenem class of antibiotics.

2013: Merck announced it would cut 8,500 jobs in an attempt to cut $2.5 billion from its costs by 2015. Combined with 7,500 job cuts announced in 2011 and 2012, the layoffs amounted to 20% of its workforce.

2014: Merck acquired Swiss biotechnology company OncoEthix for up to $375 million.

2015: Merck and Ablynx expanded their 18-month-old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for the Abylnx.

2016: Merck announced two new partnerships; the first with Quartet Medicine and its small molecule pain treatments, the second with Complix investigating intracellular cancer targets, with both collaborations potentially generating up to $595 million and $280 million respectively.

2017: Merck bought the PARP inhibitor Lynparza from AstraZeneca.

2018: Merck began the submission process for a Biologics License Application to the Food and Drug Administration under the Breakthrough Therapy Designation for an investigational vaccine, called V920, to fight the Zaire strain of the Ebola virus.

2020: Merck was one of ten companies recognised at the inaugural Manufacturing Awards by New Jersey Business magazine and the New Jersey Business and Industry Association.

2021: Merck announced it would acquire Acceleron Pharma for $11.5 billion, gaining control over Sotatercept, used in the treatment of pulmonary hypertension and luspatercept-aamt.

[Main Business Segments]

[Net Income & Total Revenue]

[Competitors]

$Zoetis(ZTS)$

$Eli Lilly and(LLY)$

$Johnson & Johnson(JNJ)$

$Bayer A.G.(BAYRY)$

$Pfizer(PFE)$

$Bayer A.G.(BAYRY)$